<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747093</url>
  </required_header>
  <id_info>
    <org_study_id>ITNK-2021</org_study_id>
    <nct_id>NCT04747093</nct_id>
  </id_info>
  <brief_title>Induced-T Cell Like NK Cells for B Cell Malignancies</brief_title>
  <official_title>Induced-T Cell Like NK Cellular Immunotherapy for Refractory B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult&#xD;
      patients. Now, there is no standard management for these patients. Induced-T cell-like NK&#xD;
      cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for&#xD;
      treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and&#xD;
      safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months</time_frame>
    <description>Overall Response Rate includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and CSF. The primary endpoint will be based on the IRC assessment. The local investigator's assessed results will be used for sensitivity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
    <description>Overall Response Rate includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and CSF. The primary endpoint will be based on the IRC assessment. The local investigator's assessed results will be used for sensitivity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 months</time_frame>
    <description>Overall Response Rate includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and CSF. The primary endpoint will be based on the IRC assessment. The local investigator's assessed results will be used for sensitivity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>1 year</time_frame>
    <description>disease-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>B Cell Leukemia</condition>
  <condition>B Cell Lymphoma</condition>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>B-cell Lymphoma Recurrent</condition>
  <condition>B-cell Lymphoma Refractory</condition>
  <arm_group>
    <arm_group_label>ITNK group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-ITNK cells</intervention_name>
    <description>CAR-ITNK cells will be infused over 10-15 minutes on Day 0.</description>
    <arm_group_label>ITNK group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with CD19 positive B-cell acute leukemia&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;2&#xD;
&#xD;
          -  ALT/ AST &lt;3 x normal&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dl and less than 2.5x normal for age&#xD;
&#xD;
          -  LVEF&lt; 45%&#xD;
&#xD;
          -  Accept white blood cell collection&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with investigational gene or cell therapy medicine products&#xD;
&#xD;
          -  Active hepatitis B , hepatitis C or HIV infection&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Presence of grade 2-4 acute or extensive chronic GVHD&#xD;
&#xD;
          -  Active CNS involvement: epilepsy, paresis, aphasia, stroke, severe head trauma,&#xD;
&#xD;
          -  Dementia, Parkinson's disease, cerebellar disease, organic brain syndrome,&#xD;
             uncontrolled mental illness, etc.&#xD;
&#xD;
          -  Any uncontrolled active medical disorder that would preclude participation as&#xD;
             outlined.&#xD;
&#xD;
          -  Received non-diagnostic purposes major surgery within the past 4 weeks&#xD;
&#xD;
          -  Participated in any other clinical study within the past 4 weeks&#xD;
&#xD;
          -  Used murine biological products (except blinatumomab), unless it is proved no&#xD;
             anti-mouse antibodies exist.&#xD;
&#xD;
          -  Pregnancy or breast-feeding women&#xD;
&#xD;
          -  Use of prohibited drugs:&#xD;
&#xD;
          -  Steroids: Therapeutic doses of steroids must be stopped &gt; 72 hours prior to ITNK Cells&#xD;
             infusion&#xD;
&#xD;
          -  Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed &gt;&#xD;
             4 weeks prior to ITNK Cells infusion&#xD;
&#xD;
          -  GVHD therapies: Any drug used for GVHD must be stopped &gt; 4 weeks prior to ITNK Cells&#xD;
             infusion&#xD;
&#xD;
          -  Any situation that may increase the risk of the test or interfere with the test&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi-fa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Lin, MD</last_name>
    <phone>+86-020-62787883</phone>
    <email>lansinglinren@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ren Lin, MD</last_name>
      <phone>+86-020-61641613</phone>
      <email>lansinglinren@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qifa Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ITNK Cells</keyword>
  <keyword>CAR</keyword>
  <keyword>B Cell Malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

